Article · 2026

Endothelial dysfunction and long-term survival in cardiovascular-kidney-metabolic syndrome stages 0-3: An EASIX-based national cohort study

Science Progress

Asiya Abudesimu; Zhonghua Sun; Ge Zhang; Xiangyu Sun; Xinliang Peng; Dilixiati Siti; Xiang Ma

Cite this paper

Plain citation

Asiya Abudesimu, Zhonghua Sun, Ge Zhang, Xiangyu Sun, Xinliang Peng, Dilixiati Siti, Xiang Ma. Endothelial dysfunction and long-term survival in cardiovascular-kidney-metabolic syndrome stages 0-3: An EASIX-based national cohort study. Science Progress. 2026;109(4):00368504261499186. https://doi.org/10.1177/00368504261499186

Author-controlled citation; verify against the publisher version of record.

Author evidence note

Research question and design

The study examined whether EASIX was associated with later mortality among 10,885 NHANES participants aged at least 30 years with cardiovascular-kidney-metabolic syndrome stages 0–3. It retrospectively analyzed survey cycles from 1999–2018, linking deaths through 2019. EASIX is calculated as lactate dehydrogenase multiplied by creatinine, divided by platelet count.

Source: PubMed PMID 42893432, Abstract Objective and Methods: population, NHANES cycles, mortality linkage and EASIX definition.

Principal quantitative findings

Over a median 97 months of follow-up, 1,122 participants died; 295 deaths were cardiovascular. Per one-unit higher EASIX, the adjusted hazard ratio was 1.41 (95% CI 1.24–1.61) for all-cause mortality and 1.30 (95% CI 1.13–1.49) for cardiovascular mortality. The abstract reports that the associations persisted after further lifestyle adjustment.

Source: PubMed PMID 42893432, Abstract Results: follow-up, deaths, adjusted HRs and CIs, one-unit exposure scale and lifestyle adjustment.

Cohort and model specification

Eligibility required a valid fasting-subsample weight and complete CKM-staging, EASIX, mortality-linkage and covariate information; participants were assigned their highest qualifying CKM stage, and stage 4 was excluded. Stage 3 included very-high-risk CKD or PREVENT 10-year total-CVD risk ≥20%; participants aged ≥80 years were assigned age 79 for PREVENT estimation. EASIX used LDH (U/L) × creatinine (mg/dL) / platelet count (10^9/L) and was modeled per one-unit increase and by quartiles. Analyses combined fasting-subsample weights with SDMVSTRA and SDMVPSU in survey-weighted Cox models. Model 2 added current smoking, BMI, systolic blood pressure, fasting glucose and antihypertensive, glucose-lowering and statin use to demographic adjustment. Follow-up ran from the baseline MEC examination to death or 31 December 2019; competing-risk analysis was a sensitivity analysis. These specifications support comparing cohort and model choices; the displayed Methods do not give the pooled-weight formula or exact cardiovascular-death codes.

Source: Published article text displayed on ResearchGate, Materials and Methods Sections 2.1–2.5 (Study Design and Population through Statistical Analysis).

Scientific contribution and publication context

The analysis connects a composite endothelial-stress index with long-term outcomes among adults at CKM stages 0–3. It provides an observational comparator for epidemiologic discussions of endothelial stress, CKM staging and mortality; survey-weighted Cox models and spline analyses supply the reported association framework. Clinical risk-assessment use requires further validation. Electronic publication is recorded as 18 October 2026. The formal journal record is Science Progress, volume 109, issue 4 (2026), article 00368504261499186.

Source: PubMed PMID 42893432, Abstract Methods and Conclusions: survey-weighted Cox models, restricted cubic splines, CKM stage scope and risk-assessment interpretation. PubMed ArticleDate DateType=Electronic 2026-10-18; Crossref volume 109, issue 4, article-number 00368504261499186 and published-print [2026,10].

Evidence scope and limitations

Author-maintained explanation of an observational mortality analysis in CKM stages 0–3, supported by the indexed abstract and source-located reading of the published Methods.

Provenance

Source review: 2026-11-15.

Author-controlled academic record for Ge Zhang (张格; ORCID 0000-0002-3116-3246). This page identifies the work as part of Ge Zhang’s publication record. It does not replace the publisher version or assert a complete author list.